Who is sponsoring NCT06258447?

NCT06258447 is sponsored by BioCardia, Inc..

What condition does NCT06258447 study?

NCT06258447 studies Ischemic Heart Failure.

Is NCT06258447 still recruiting?

NCT06258447 is currently recruiting now. Last updated 9 February 2026.

Last reviewed 2026-02-09 · How we verify

NCT06258447

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With Reduced Ejection Fraction

Recruiting now NA Last updated 9 February 2026

What this trial tests

NA trial testing Autologous bone marrow mononuclear cells processed / delivered using the CardiAMP cell therapy system in Ischemic Heart Failure in 250 participants. Currently enrolling.

Timeline

1 August 2024

Primary endpoint
1 April 2027

1 April 2029

Quick facts

Lead sponsor	BioCardia, Inc.
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	250
Start date	1 August 2024
Primary completion	1 April 2027
Estimated completion	1 April 2029
Sites	5 locations across United States

Drugs / interventions tested

Autologous bone marrow mononuclear cells processed / delivered using the CardiAMP cell therapy system

Conditions studied

Ischemic Heart Failure — all drugs for Ischemic Heart Failure →

Sponsor

BioCardia, Inc. — full company profile →

Who can join

Adults 21 to 90, any sex, with Ischemic Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Concentrated autologous bone marrow mononuclear cells (ABM MNC) contain potentially therapeutic cell factors and past studies support therapeutic benefit to patients with cardiac diseases of acute myocardial infarction, ischemia, and heart failure when utilized as this study is designed. The purpose of the study is to determine the safety and efficacy of CardiAMP cell therapy system in patients with ischemic heart failure. It is a prospective, multi-center, randomized, controlled, patient and evaluator-blinded study comparing treatment with the CardiAMP cell therapy system to a control procedure with diagnostic catheterization.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Stem cell therapy for patients with acute myocardial infarction: a systematic review of clinical trials.
Mahram H, Khalafi V, Arman A, Mirhosseini SA, et al · · 2025 · PMID 41469916 · DOI 10.1186/s13287-025-04882-6

Verify or expand the search:

Other BioCardia, Inc. trials

Trials by the same sponsor.

NCT05491681 — AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06258447 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BioCardia, Inc.
Last refreshed: 9 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06258447.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing